Welcome to our dedicated page for Unicycive Therapeutics news (Ticker: UNCY), a resource for investors and traders seeking the latest updates and insights on Unicycive Therapeutics stock.
Unicycive Therapeutics develops investigational treatments for kidney diseases, with news centered on its clinical-stage pipeline, regulatory communications, financial results, and investor presentations. Its lead program, oxylanthanum carbonate, is an oral phosphate binder being developed for hyperphosphatemia in chronic kidney disease patients on dialysis, and company updates frequently address NDA activity, chemistry, manufacturing and controls matters, and commercial-readiness planning.
Unicycive also reports developments for UNI-494, a drug candidate for conditions related to acute kidney injury, including its FDA orphan drug designation for prevention of delayed graft function in kidney transplant patients and completed Phase 1 safety work. Recurring announcements include business updates, conference participation, and capital or cash-position disclosures tied to advancing the kidney-disease portfolio.
Unicycive Therapeutics (Nasdaq: UNCY) reported its Q3 2021 financial results, showing a net loss of $5.2 million, or $0.37 per share, a dramatic rise from a $0.7 million loss in Q3 2020. Key developments include the addition to the Russell Microcap Index and the hiring of Douglas Jermasek as Executive VP of Corporate Strategy. The company anticipates confirmatory guidance from the FDA regarding its lead drug, Renazorb, aimed at treating hyperphosphatemia in chronic kidney disease, in Q4 2021.
Unicycive Therapeutics, a clinical-stage biotechnology firm focused on kidney disease therapies, has appointed Douglas Jermasek as Executive Vice President, Corporate Strategy. Jermasek brings over 25 years of industry experience, including significant roles at Akebia and Genzyme, where he drove over $1 billion in sales. His expertise in kidney disease therapy is expected to enhance Unicycive’s corporate and commercial strategies. This appointment signals the company’s commitment to addressing challenges in kidney care and advancing its lead drug, Renazorb, aimed at treating hyperphosphatemia.
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) will be added to the Russell Microcap® Index on September 20, 2021, enhancing its visibility and recognition within the investment community. This membership, which lasts for one year, will link Unicycive with over $17.9 trillion in assets benchmarked to Russell indexes. CEO Shalabh Gupta emphasized that this milestone will drive further interest in Unicycive's clinical programs as a newly public company. The inclusion reflects Unicycive's market-capitalization ranking and style attributes determined by FTSE Russell.
Unicycive Therapeutics, a clinical stage biotechnology firm focused on kidney disease therapies, announced that CEO Shalabh Gupta will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast link will be available on the Unicycive website's Investors section on September 13, with an archive accessible for three months. Unicycive's lead drug, Renazorb, targets hyperphosphatemia, while UNI-494 is in late preclinical development for acute kidney injury. For further details, visit www.unicycive.com.
Unicycive Therapeutics, a clinical-stage biotechnology firm focused on kidney disease treatments, disclosed its Q2 2021 financial results. The company raised $25 million from its recent IPO and plans to meet the FDA in Q4 2021 regarding its lead product Renazorb. R&D expenses increased to $0.5 million from $0.2 million year-over-year, and net loss rose to $1.1 million or $0.13 per share. The company is working on the investigational drug UNI-494 and expects significant milestones in the upcoming periods.